scholarly journals Patient perspectives of the influence of severe and non‐severe asthma on their quality of life: a national survey of asthma patients in Spain

2021 ◽  
Author(s):  
Eusebi Chiner ◽  
Carme Hernández ◽  
Marina Blanco Aparicio ◽  
Eunice Funenga Fitas ◽  
Carlos Jiménez‐Ruiz
Keyword(s):  
Quality Of Life ◽  
Severe Asthma ◽  
National Survey ◽  
Patient Perspectives ◽  
Asthma Patients

scholarly journals A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use

2016 ◽  
Vol 48 (3) ◽  
pp. 726-733 ◽  
Author(s):  
Akke-Nynke van der Meer ◽  
Henk Pasma ◽  
Wilma Kempenaar-Okkema ◽  
Jo-Anneke Pelinck ◽  
Myrte Schutten ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Asthma Control ◽  
Severe Asthma ◽  
Life Questionnaire ◽  
Healthcare Use ◽  
Uncontrolled Asthma ◽  
Control Quality ◽  
Asthma Patients

Patients with uncontrolled asthma report ongoing symptoms, poor quality-of-life and extensive healthcare use (HCU) and might benefit from management by a specialised severe asthma team. It is unknown whether a one-time evaluation by asthma experts, without long-term supervision by a specialised team, provides favourable outcomes. We evaluated asthma control (Asthma Control Questionnaire; ACQ), quality-of-life (Asthma-related Quality of Life Questionnaire; AQLQ) and HCU before and 1 year after a 1-day visit programme in a severe asthma centre, including a multidisciplinary assessment resulting in a personalised management plan to be implemented by patients own pulmonologists.40 uncontrolled asthma patients completed questionnaires (ACQ, AQLQ, HCU) at baseline, and 6 and 12 months follow-up.ACQ improved from 2.6 (interquartile range 1.7–3.2) to 1.8 (1.2–3.2) (p=0.003) and AQLQ from 4.8 (4.0–5.2) to 5.3 (4.4–6.0) (p<0.001). We found a reduction in patients with ≥2 exacerbations (95% versus 17%; p<0.001), ≥1 emergency room visit (78% versus 37%; p<0.001) and ≥1 hospitalisation (47% versus 10%; p=0.001).Evaluation of uncontrolled asthma patients in a 1-day visit programme in a severe asthma centre resulted in significant improvements in asthma control, quality-of-life and healthcare use after 1 year. This 1-day visit approach seems beneficial for uncontrolled asthma patients and might reduce their dependence on expensive treatment modalities and long-term management in specialised centres.

scholarly journals Health-related Quality of Life and Productivity Among a Real-World Cohort of Severe Asthma Patients in the United States

2020 ◽  
Vol 145 (2) ◽  
pp. AB204
Author(s):  
Weily Soong ◽  
Bradley Chipps ◽  
Jennifer Trevor ◽  
Warner Carr ◽  
Sean O’Quinn ◽  
...  
Keyword(s):  
Quality Of Life ◽  
United States ◽  
Severe Asthma ◽  
Real World ◽  
The United States ◽  
Health Related Quality ◽  
Asthma Patients ◽  
Related Quality ◽  
Health Related

scholarly journals COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 853
Author(s):  
Marco Caminati ◽  
Gabriella Guarnieri ◽  
Veronica Batani ◽  
Elena Scarpieri ◽  
Anita Finocchiaro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Disease Control ◽  
Severe Asthma ◽  
Vaccination Campaign ◽  
Tolerability Profile ◽  
Life Questionnaire ◽  
Biologic Treatment ◽  
Asthma Patients

Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.

Late Breaking Abstract - Second Souffle: preliminary results from a national survey on the care pathways and quality of life of patients with T2 severe asthma

2021 ◽  
Author(s):  
Alain Didier ◽  
Chantal Raherison-Semjen ◽  
Edouard VERDIER ◽  
Claire Camus ◽  
Christophe Pison ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Severe Asthma ◽  
National Survey ◽  
Care Pathways ◽  
Preliminary Results

Research of quality of life of COPD and asthma patients

Pneumologie ◽  
2005 ◽  
Vol 59 (S 1) ◽  
Author(s):  
T Zhukava
Keyword(s):  
Quality Of Life ◽  
Asthma Patients

scholarly journals Comparison of the effects of pulmonary and extra-pulmonary symptoms on health-related quality of life in patients with severe asthma

2020 ◽  
Vol 162 ◽  
pp. 105870 ◽  
Author(s):  
Joseph W. Lanario ◽  
Michael E. Hyland ◽  
Yinghui Wei ◽  
Rupert C. Jones ◽  
Matthew Masoli
Keyword(s):  
Quality Of Life ◽  
Severe Asthma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Extra Pulmonary
Sign in / Sign up

Export Citation Format

Share Document